Exploring the clinical significance of miR‐148 expression variations in distinct subtypes of irritable bowel syndrome

Abstract

Irritable bowel syndrome (IBS) belongs to chronic functional gastrointestinal diseases featured by abdominal pain and changes in bowel habits. This study aimed to investigate the clinical significance of serum miR‐148 expression in different subtypes of IBS. We enrolled 86 IBS patients and 55 healthy controls. miR‐148 expression levels were assessed in IBS patients classified into IBS‐constipation (IBS‐C), IBS‐diarrhea (IBS‐D), and IBS‐mixed stool pattern (IBS‐M) subtypes. Receiver‐operating characteristic (ROC) curves were employed to evaluate the diagnostic potential of miR‐148 in distinguishing among IBS subtypes. Additionally, we analyzed the correlation between miR‐148 expression and clinical characteristics, including IBS symptom severity. miR‐148 expression was highest in IBS‐D (diarrhea) group, followed by IBS‐M and IBS‐C. With the exception of the IBS‐C group, miR‐148 expression was elevated in IBS patients compared to controls. ROC curve analysis demonstrated that serum miR‐148 exhibited higher diagnostic accuracy for discriminating IBS‐C and IBS‐D than IBS‐M. Correlation analysis revealed a positive relationship between serum miR‐148 relative expression and IBS symptom severity system scores. Univariate logistic analysis indicated a positive association between miR‐148 expression and IBS‐D and a negative correlation with IBS‐C. miR‐148 expression exhibits differential patterns among IBS subtypes and holds a potential to distinguish IBS‐C and IBS‐D. Furthermore, miR‐148 expression correlates with the severity of IBS symptoms.